American Association for Cancer Research

Table 1

Clinical data on patient disease courses and results of molecular CIS^a classification

Sample group^b	Patient^c	Previous tumors	Tumor analyzed	Subsequent tumors	CIS^d	CIS classifier^e
1	1060-1		Ta gr2	2 Ta	No	No CIS
1	1146-1		Ta gr2		No	No CIS
1	1216-1		Ta gr2		No	No CIS
1	1303-1		Ta gr2		No	No CIS
1	524-1		Ta gr2		No	No CIS
1	692-1		Ta gr2	2 Ta	No	No CIS
1	1264-1		Ta gr3	20 Ta	No	No CIS
1	1350-1		Ta gr3	1 Ta	No	No CIS
1	1354-1		Ta gr3	3 T1	No	No CIS
1	775-1		Ta gr3	1 Ta	No	No CIS
1	1066-1		Ta gr3	1 Ta	No	No CIS
1	1276-1		Ta gr3	2 T1	No	No CIS
1	1070-1		Ta gr3	1 Ta	No	No CIS
1	989-1		Ta gr3		No	No CIS
1	1482-1		Ta gr3	20 Ta	No	CIS
2	1345-2	1 T1	Ta gr3		Sampling visit	CIS
2	1062-2	1 Ta	Ta gr3	1 T1	Sampling visit	CIS
2	956-2	1 Ta	Ta gr3	1 Ta	Sampling visit	CIS
2	320-7	1 Ta, 2 T1	Ta gr3	2 Ta	Sampling visit	CIS
2	1330-1		Ta gr3		Sampling visit	CIS
2	602-8	5 Ta	Ta gr3	3 Ta	Sampling visit	CIS
2	763-1		Ta gr2	14 Ta	Sampling visit	CIS
2	1024-1		T1 gr3	2 Ta, 1 T1	Sampling visit	CIS
2	1182-1		Ta gr3	7 Ta	Subsequent visit	CIS
2	1093-1		Ta gr3	4 Ta, 1 T1	Subsequent visit	CIS
2	797-1		Ta gr3		Sampling visit	CIS
2	1337-1	1 Ta	T1 gr3		Sampling visit	CIS
2	1625-1		Ta gr2		Sampling visit	CIS
3	1015-1		T3b gr4		No	—
3	1385-1		T4a gr3		Sampling visit	—
3	1041-1		T4b gr3		No	—
3	1044-1		T4b gr3		ND	—
3	1055-1	1 Ta gr2	T3a gr3		No	—
3	1109-1		T2 gr3	1 T2-4	No	—
3	1124-1		T4a gr3	2 T2-4	No	—
3	1154-1		T3a gr3	1 Ta, 1 T2-4	No	—
3	1167-1	1 T2-4	T3b gr4	2 T2-4	ND	—
3	1178-1		T4b gr3		ND	—
3	1215-1		T4b gr3		ND	—
3	1271-1		T3b gr4		No	—
3	1321-1	1 T1	T3b gr?		ND	—

Sample group^b	Patient^c	Previous tumors	Tumor analyzed	Subsequent tumors	CIS^d	CIS classifier^e
1	1060-1		Ta gr2	2 Ta	No	No CIS
1	1146-1		Ta gr2		No	No CIS
1	1216-1		Ta gr2		No	No CIS
1	1303-1		Ta gr2		No	No CIS
1	524-1		Ta gr2		No	No CIS
1	692-1		Ta gr2	2 Ta	No	No CIS
1	1264-1		Ta gr3	20 Ta	No	No CIS
1	1350-1		Ta gr3	1 Ta	No	No CIS
1	1354-1		Ta gr3	3 T1	No	No CIS
1	775-1		Ta gr3	1 Ta	No	No CIS
1	1066-1		Ta gr3	1 Ta	No	No CIS
1	1276-1		Ta gr3	2 T1	No	No CIS
1	1070-1		Ta gr3	1 Ta	No	No CIS
1	989-1		Ta gr3		No	No CIS
1	1482-1		Ta gr3	20 Ta	No	CIS
2	1345-2	1 T1	Ta gr3		Sampling visit	CIS
2	1062-2	1 Ta	Ta gr3	1 T1	Sampling visit	CIS
2	956-2	1 Ta	Ta gr3	1 Ta	Sampling visit	CIS
2	320-7	1 Ta, 2 T1	Ta gr3	2 Ta	Sampling visit	CIS
2	1330-1		Ta gr3		Sampling visit	CIS
2	602-8	5 Ta	Ta gr3	3 Ta	Sampling visit	CIS
2	763-1		Ta gr2	14 Ta	Sampling visit	CIS
2	1024-1		T1 gr3	2 Ta, 1 T1	Sampling visit	CIS
2	1182-1		Ta gr3	7 Ta	Subsequent visit	CIS
2	1093-1		Ta gr3	4 Ta, 1 T1	Subsequent visit	CIS
2	797-1		Ta gr3		Sampling visit	CIS
2	1337-1	1 Ta	T1 gr3		Sampling visit	CIS
2	1625-1		Ta gr2		Sampling visit	CIS
3	1015-1		T3b gr4		No	—
3	1385-1		T4a gr3		Sampling visit	—
3	1041-1		T4b gr3		No	—
3	1044-1		T4b gr3		ND	—
3	1055-1	1 Ta gr2	T3a gr3		No	—
3	1109-1		T2 gr3	1 T2-4	No	—
3	1124-1		T4a gr3	2 T2-4	No	—
3	1154-1		T3a gr3	1 Ta, 1 T2-4	No	—
3	1167-1	1 T2-4	T3b gr4	2 T2-4	ND	—
3	1178-1		T4b gr3		ND	—
3	1215-1		T4b gr3		ND	—
3	1271-1		T3b gr4		No	—
3	1321-1	1 T1	T3b gr?		ND	—

CIS, carcinoma in situ; sTCC, superficial transitional cell carcinoma; ND, not determined.

The tumor groups involved were sTCC without CIS (1), sTCC with CIS (2), and mTCC (3).

The numbers indicate the patient number followed by a number indicating number of visit in the clinic.

CIS in selected site biopsies in previous, present, or subsequent visits to the clinic.

Molecular classification of the samples using 25 genes in cross-validation loops.